Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors

Journal of Clinical Oncology

Volumn 29, Issue 21, 2011, Pages 2933-2940

  Spunt, Sheri L ^a,b   Grupp, Stephan A ^c   Vik, Terry A ^e   Santana, Victor M ^a,b   Greenblatt, David J ^f   Clancy, Jill ^g   Berkenblit, Anna ^d   Krygowski, Mizue ^d   Ananthakrishnan, Revathi ^g   Boni, Joseph P ^d   Gilbertson, Richard J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d PFIZER INC   (United States)

^e RILEY HOSPITAL FOR CHILDREN   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g inVentiv Clinical Solutions ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; TEMSIROLIMUS;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER GRADING; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPENDYMOMA; FEMALE; GERM CELL TUMOR; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPOKALEMIA; HYPOPROTEINEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MUCOSA INFLAMMATION; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUROECTODERM TUMOR; NEUTROPENIA; OSTEOSARCOMA; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PONTINE GLIOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECURRENT CANCER; RHABDOID TUMOR; RHABDOMYOSARCOMA; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; TERATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79960744694     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.4649     Document Type: Conference Paper

References (41)

1. Bjornsti MA, Houghton PJ: The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4:335-348, 2004
2. Dancey JE: Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 5:1065-1073, 2006
3. Meric-Bernstam F, Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287, 2009
4. Aoki M, Blazek E, Vogt PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136-141, 2001 (Pubitemid 32095876)
5. Hara K, Yonezawa K, Kozlowski MT, et al: Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272:26457-26463, 1997 (Pubitemid 27458864)
6. Sarbassov DD, Guertin DA, Ali SM, et al: Phosphorylation and regulation of Akt/PKB by the rictormTOR complex. Science 307:1098-1101, 2005 (Pubitemid 40262113)
7. Dudkin L, Dilling MB, Cheshire PJ, et al: Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758-1764, 2001 (Pubitemid 32708646)
8. Podsypanina K, Lee RT, Politis C, et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98:10320-10325, 2001 (Pubitemid 32803018)
9. Thomas GV, Tran C, Mellinghoff IK, et al: Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12:122-127, 2006 (Pubitemid 43050086)
10. Yu K, Toral-Barza L, Discafani C, et al: MTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249-258, 2001 (Pubitemid 32947647)
11. Wu C, Wangpaichitr M, Feun L, et al: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4:25, 2005
12. Asano T, Yao Y, Zhu J, et al: The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 331:295-302, 2005 (Pubitemid 40545175)
13. Wu L, Birle DC, Tannock IF: Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 65:2825-2831, 2005 (Pubitemid 40490085)
14. Teachey DT, Grupp SA, Brown VI: Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145:569-580, 2009
15. Yazbeck VY, Buglio D, Georgakis GV, et al: Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 36:443-450, 2008 (Pubitemid 351384743)
16. Teachey DT, Obzut DA, Cooperman J, et al: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107:1149-1155, 2006 (Pubitemid 43156317)
17. Shi Y, Gera J, Hu L, et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62:5027-5034, 2002 (Pubitemid 34984430)
18. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
19. Raymond E, Alexandre J, Faivre S, et al: Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336-2347, 2004 (Pubitemid 41115390)
20. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003 (Pubitemid 36993245)
21. Coulter DW, Blatt J, D'Ercole AJ, et al: IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res 28:1509-1516, 2008 (Pubitemid 351892923)
22. Dilling MB, Dias P, Shapiro DN, et al: Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res 54:903-907, 1994 (Pubitemid 24085438)
23. Geoerger B, Kerr K, Tang CB, et al: Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 61:1527-1532, 2001 (Pubitemid 34292583)
24. Hosoi H, Dilling MB, Liu LN, et al: Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 54:815-824, 1998 (Pubitemid 28523173)
25. Wan X, Shen N, Mendoza A, et al: CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 8:394-401, 2006 (Pubitemid 43830746)
26. Geoerger B, Kieran MW, Grupp S, et al: Phase 2 study of temsirolimus in children with high-grade glioma, neurosarcoma, and rhabdomyosarcoma. J Clin Oncol 28:688s, 2010 (suppl; abstr 9541)
27. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
28. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
29. Fouladi M, Laningham F, Wu J, et al: Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25:4806-4812, 2007 (Pubitemid 350086485)
30. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004 (Pubitemid 41103603)
31. Chan S, Scheulen ME, Johnston S, et al: Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322, 2005 (Pubitemid 46206985)
32. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304, 2005 (Pubitemid 46206983)
33. Hidalgo M, Buckner JC, Erlichman C, et al: A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755-5763, 2006 (Pubitemid 44629606)
34. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347-5356, 2005 (Pubitemid 46206988)
35. Hu X, Pandolfi PP, Li Y, et al: MTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7:356-368, 2005 (Pubitemid 40664225)
36. Misawa A, Hosoi H, Tsuchiya K, et al: Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 104:233-237, 2003 (Pubitemid 36249800)
37. Hosoi H, Dilling MB, Shikata T, et al: Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59:886-894, 1999 (Pubitemid 29086744)
38. Cao L, Yu Y, Darko I, et al: Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 68:8039-8048, 2008
39. Doherty L, Gigas DC, Kesari S, et al: Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158, 2006 (Pubitemid 44305484)
40. Gallicchio MA, van Sinderen M, Bach LA: Insulin-like growth factor binding protein-6 and CCI-779, an ester analogue of rapamycin, additively inhibit rhabdomyosarcoma growth. Horm Metab Res 35:822-827, 2003 (Pubitemid 38058189)
41. Kurmasheva RT, Dudkin L, Billups C, et al: The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 69:7662-7671, 2009